NEW YORK--(BUSINESS WIRE)--Neuro-Hitech, Inc. (NASDAQ: NHPI), a biopharmaceutical company focused on the development and commercialization of next-generation compounds for neurodegenerative diseases, today announced that Alan Kestenbaum, a director and founder of the company, terminated a pre-arranged stock trading plan previously adopted by him in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Transactions under the stock trading plan were publicly disclosed through Form 144 and Form 4 filings with the Securities and Exchange Commission.
